ClearPoint Neuro, Inc. (MRI Interventions, Inc. in the filing) — Q2 2014 Form 10-Q
Business context and reporting period. The unaudited report covers the three and six months ended June 30, 2014. The company develops MRI-guided minimally invasive procedure systems. ClearPoint was commercially marketed for neurological procedures; ClearTrace, intended for cardiac procedures, remained under development and was not cleared for commercial sale.
Financial results and liquidity
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Total revenue | $1.189 million (2013: $562,000) | $2.011 million (2013: $1.827 million) |
| Net income (loss) | $(1.593) million (2013: $(1.352) million) | $1.037 million (2013: $(2.176) million) |
| Operating income (loss) | $(2.216) million (2013: $(2.178) million) | $(24,000) (2013: $(3.545) million) |
| Cash used in operations | Not separately reported for the quarter | $3.081 million (2013: $4.429 million) |
- Q2 product revenue was $1.155 million, up from $497,000; development-service revenue fell to $5,000 from $65,000. H1 product revenue was $1.868 million, compared with $958,000.
- Gross profit on product revenue was approximately $578,000 in Q2 (about 50% margin) and $940,000 for H1 (about 50% margin), based on reported product revenue and product costs.
- H1 net income included a $4.339 million gain on sale of intellectual property and a $1.359 million noncash gain from changes in the fair value of warrant liabilities. The reported near break-even operating result also reflects the intellectual-property gain; it does not indicate profitable ongoing operations.
- At June 30, cash and cash equivalents were $4.076 million, total current assets $6.670 million, and current liabilities $4.755 million. Working capital was approximately $1.915 million. Total liabilities were $12.985 million against assets of $8.477 million; stockholders’ deficit was $4.509 million.
- Cash increased by $560,000 in H1, including $3.646 million of financing inflows, principally net proceeds from a debt offering. Capital expenditures were $5,000.
Material changes and financing
- In March 2014, the company sold certain intellectual property to Boston Scientific for $4.339 million, satisfied through cancellation of related-party convertible notes of the same amount. This discharged the notes and released their liens. The company also gave up potential future milestone payments and royalties under amended Boston Scientific agreements; the transaction did not affect ClearPoint commercialization or ClearTrace development.
- The March private offering raised $3.725 million gross through five-year, 12% second-priority secured notes and warrants; reported net proceeds were $3.503 million. The notes are non-convertible, mature in 2019, and are subordinated to the Brainlab senior secured note.
- Product and other service revenue increased, reflecting higher disposable-product demand, reusable-system sales, installation and service revenue, and some contract manufacturing. H1 development-service and license revenue declined; the 2013 comparison included $650,000 of Boston Scientific license revenue.
- Research and development and selling, general and administrative expenses rose year over year. Management attributed much of the R&D increase to ClearTrace development and the SG&A increase to sales and marketing.
Outlook, risks, and unusual items
- Management expected ClearPoint product revenue to increase during the remainder of 2014, supported by sales and clinical-support team additions, and believed cash plus expected product-sale proceeds would fund anticipated requirements through at least December 2014. This was management’s estimate, not a guarantee.
- The company expected continued operating cash use and losses. If funding proved insufficient, it might seek equity, debt, or credit financing, or modify its business plan; additional equity or convertible financing could dilute shareholders. Management identified possible spending deferrals and other cost reductions.
- Key risks include limited ClearPoint market adoption and reimbursement uncertainty; dependence on suppliers and manufacturing capacity; ClearTrace development and regulatory uncertainty; competition, product liability, intellectual-property protection, and the need for additional capital.
- A Summer Street Research Partners arbitration was settled in July 2014 for a $20,000 payment, and the proceeding was dismissed. The filing also disclosed approximately $150,000 plus expenses for a consulting engagement and approximately $100,000 payable under another service-provider agreement.
- Disclosure controls and procedures were assessed as effective at June 30, 2014; no material change in internal control over financial reporting was reported for the quarter.
Important facts for investors to verify
- Whether ClearPoint sales growth and recurring disposable-product demand continue, and whether product margins improve with scale.
- Cash burn, remaining liquidity, and the assumptions behind management’s stated runway through December 2014.
- The economics and accounting of the Boston Scientific asset sale, including the lost future royalty and milestone potential.
- Debt terms, interest burden, security priority, and any future financing or dilution requirements.
- ClearTrace development progress, regulatory pathway, and funding needs; it was not approved for commercial sale as of the filing.